Analysts Conflicted on These Healthcare Names: CSPC Pharmaceutical Group (OtherCHJTF) and Moderna (MRNA)
Confident Investing Starts Here:
CSPC Pharmaceutical Group (CHJTF)
Jefferies analyst Chu Wang downgraded CSPC Pharmaceutical Group to Sell yesterday and set a price target of HK$5.00. The company's shares closed last Tuesday at $0.81.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for CSPC Pharmaceutical Group with a $0.84 average price target.
Moderna (MRNA)
In a report issued on May 31, Courtney Breen from Bernstein maintained a Hold rating on Moderna. The company's shares closed last Friday at $26.56.
According to TipRanks.com, Breen is a 2-star analyst with an average return of -0.1% and a 27.8% success rate. Breen covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, Merck & Company, and Gilead Sciences.
Moderna has an analyst consensus of Hold, with a price target consensus of $49.36, implying an 87.4% upside from current levels. In a report issued on May 27, Barclays also maintained a Hold rating on the stock with a $40.00 price target.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
21 hours ago
- Business Insider
DBS downgrades Cathay Pacific Airways (CPCAF) to a Hold
Cathay Pacific Airways received a Hold rating and an HK$11.00 price target from DBS analyst Jason Sum today. The company's shares closed yesterday at $1.31. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Sum covers the Industrials sector, focusing on stocks such as SIA Engineering Co, SIA – Singapore Airlines, and Boeing. According to TipRanks, Sum has an average return of 16.6% and a 73.77% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Sell analyst consensus rating for Cathay Pacific Airways with a $1.30 average price target, implying a -0.76% downside from current levels. In a report released on August 7, TR | OpenAI – 4o also downgraded the stock to a Hold with a HK$11.50 price target.
Business Insider
21 hours ago
- Business Insider
WH Group (WHGRF) Gets a Buy from DBS
In a report released today, Clement Xu from DBS maintained a Buy rating on WH Group , with a price target of HK$8.70. The company's shares closed last Friday at $1.01. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Xu is a 4-star analyst with an average return of 8.6% and a 66.10% success rate. Xu covers the Consumer Defensive sector, focusing on stocks such as China Resources Beer (Holdings) Co, Budweiser Brewing Co. APAC Ltd., and WH Group . WH Group has an analyst consensus of Strong Buy, with a price target consensus of $1.13. Based on WH Group 's latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $13.65 billion and a net profit of $828 million. In comparison, last year the company earned a revenue of $6.75 billion and had a net profit of $44 million
Bloomberg
a day ago
- Bloomberg
Other Nations Move Toward Making Their Own Vaccines as US Cuts Funding
At least a dozen countries are interested in developing their own vaccines because they're losing confidence that the US government will have immunizations ready for the next pandemic, a top biotech investor said. Other nations have largely depended on the US to make shots that are deployed globally. The Covid-19 vaccines, developed by Pfizer Inc. and Moderna Inc. and embraced by the US government, were used by tens of millions of people around the world.
